A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
Condition(s):Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma; Clear Cell CarcinomaLast Updated:November 21, 2023Not yet recruiting